All In Biotech

Drug Trial Radar · NCT07356466

Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Center Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

100

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

Apr 30, 2027

Study completion Apr 30, 2030

Sponsor

Lead sponsor
Fujian Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the objective response rate (ORR) of Pembrolizumab combined with Lenvatinib and SOX compared with SOX alone in the treatment of patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.

Conditions

  • Gastric (Stomach) Cancer

Interventions

  • Pucotenlimab Combined with LenvatinibDrug

    Pucotenlimab Combined with Lenvatinib

  • Oxaliplatin plus S-1 regimenDrug

    Oxaliplatin plus S-1 regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: 30day
  2. Objective Response RateTime frame: 30day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.